Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

Inclusion Criteria: * 18 years of age or older * Anterior circulation aneurysm * Patients who have undergone surgical intervention * Absence of rebleeding or new intracranial hemorrhage noted on post-intervention CT scan * Consent for study participation Exclusion Criteria: * Non-aneurysmal subarachnoid hemorrhage * Multiple ruptured aneurysms * Patients with congestive heart failure * Severe aneurysmal subarachnoid hemorrhage (Hunt Hess Grade V) * Active pathological bleeding * Allergy to cilostazol * Positive pregnancy test * Coagulopathy not caused by anti-coagulant use * History of hemorrhagic complications (gastrointestinal bleeding, etc) * Uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol * Patients requiring anticoagulant/antiplatelet treatment following intervention (e.g. stent-assisted coiling or flow-diverting stent obliteration of aneurysm)